Cubist Pharmaceuticals Newswire

Cubist Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Cubist Pharmaceuticals.

Results 1 - 20 of 38 in Cubist Pharmaceuticals

  1. Shufro Rose & Co. LLC Sells 7,047 Shares of Lexington Realty TrustRead the original story w/Photo

    Sunday Oct 28 | Daily Political

    Shufro Rose & Co. LLC decreased its position in Lexington Realty Trust by 30.8% in the 3rd quarter, HoldingsChannel reports.

    Comment?

  2. 638,120 Shares in Lexington Realty Trust (LXP) Purchased by Peregrine Capital Management LLCRead the original story w/Photo

    Monday Oct 22 | AmericanBankingNews.com

    Peregrine Capital Management LLC bought a new position in shares of Lexington Realty Trust in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 638,120 shares of the real estate investment trust's stock, valued at approximately $5,296,000.

    Comment?

  3. Mass. antibiotics developers say the field is getting slowly betterRead the original story w/Photo

    Aug 30, 2018 | Business Journal

    ... And four years ago, the world's largest biotech devoted to antibiotics, Lexington drug giant Cubist Pharmaceuticals was acquired by Merck, which has a limited antibiotic pipeline. Cubist had demonstrated the potential of antibiotic development, with ...

    Comment?

  4. For Paratek, Only A Matter Of Time Before Stock Rises.EventuallyRead the original story w/Photo

    Aug 26, 2018 | Seeking Alpha

    ... tedizolid phosphate, Merck's ( MRK ) Sivextro. Sivextro was a big story back in 2013 and 2014 when Cubist Pharmaceuticals first acquired Trius, which developed tedizolid through Phase III, followed by Merck's acquisition of Cubist in 2014. ...

    Comment?

  5. Kaleido Biosciences Announces Appointment of Alison Lawton as Chief Executive OfficerRead the original story w/Photo

    Aug 21, 2018 | The Galveston County Daily News

    ... of Directors at ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta Therapeutics. Mr. Brumm joined Kaleido as its CFO in April 2018 and will continue to ...

    Comment?

  6. Hospital Infection Therapeutics Market to Grow Due to Increasing...Read the original story w/Photo

    Aug 13, 2018 | SBWire

    ... stol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc. Enquiry for discount on this report -

    Comment?

  7. Concert Pharmaceuticals Inc.'s (CNCE) CEO Roger Tung on Q2 2018 Results - Earnings Call TranscriptRead the original story w/Photo

    Aug 4, 2018 | Seeking Alpha

    Good day ladies and gentlemen and welcome to the Concert Pharmaceuticals' Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  8. Dow 30 Earnings: Merck Second Quarter 2018Read the original story

    Jul 27, 2018 | Value Line

    ... n 2014, the company made three significant acquisitions: Schering-Plough, Idenix Pharmaceuticals, and Cubist Pharmaceuticals. At the time of this article's writing, the author did not have positions in any of the companies mentioned.

    Comment?

  9. A troubling exit: Drug company ends antibiotics researchRead the original story w/Photo

    Jul 22, 2018 | Star Tribune

    A lab at the erstwhile Cubist Pharmaceuticals in 2010. As recent developments involving another drug manufacturer show, maintaining a steady flow of new drugs in development is vital because the bacteria that cause infectious diseases evolve to become less susceptible to treatments.

    Comment?

  10. Cubist Systematic Strategies LLC Decreases Stake in Atlas Air Worldwide Holdings, Inc.Read the original story w/Photo

    Jul 12, 2018 | IntersportsWire

    Cubist Systematic Strategies LLC trimmed its stake in shares of Atlas Air Worldwide Holdings, Inc. by 43.3% in the 1st quarter, Holdings Channel reports. The firm owned 3,788 shares of the transportation company's stock after selling 2,893 shares during the period.

    Comment?

  11. Feuer v. Merck Co IncRead the original story w/Photo

    Jun 1, 2018 | FindLaw

    ... itself and senior management responsible for Merck's acquisition of another pharmaceutical firm, Cubist Pharmaceuticals, Inc. Feuer asserted the acquisition was ill-advised and reckless. He alleged Merck proceeded with the transaction although it ...

    Comment?

  12. ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical DevelopmentRead the original story w/Photo

    May 21, 2018 | The Galveston County Daily News

    ... and Alliance Management at Juniper Pharmaceuticals. Previously, Joyce held leadership positions at Cubist Pharmaceuticals, where she was Senior Director, Program and Portfolio Management and at Genzyme, a Sanofi Company, where she was Senior ...

    Comment?

  13. Feds: Biogen, Shire using tactics to thwart genericsRead the original story w/Photo

    May 18, 2018 | Boston Herald

    ... reports of difficulties obtaining Firazyr, which treats hereditary angioedema, a genetic disorder. Cubist Pharmaceuticals and Aegerion were also included on the list. "Shire is committed to developing therapies for rare diseases and specialized ...

    Comment?

  14. Hospital Infection Therapeutics Market Expected to Witness a Sustainable Growth by 2020Read the original story w/Photo

    Apr 20, 2018 | SBWire

    ... stol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Pfizer, Inc., AstraZeneca plc, and Cubist Pharmaceuticals, Inc. Enquiry for discount on this report - 1280

    Comment?

  15. Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective...Read the original story

    Apr 5, 2018 | Customer Interaction Solutions

    ... in the coming years." Prior to joining Trevena, Ms. Bourdow was vice president of marketing at Cubist Pharmaceuticals, Inc., until its acquisition by Merck & Co., Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, ...

    Comment?

  16. ImmusanT Adds Robert J. Perez to Board of DirectorsRead the original story w/Photo

    Apr 4, 2018 | Business Wire

    Mr. Perez is the first independent member of the ImmusanT Board, which includes representatives from investors ARCH Venture Partners and Vatera Holdings LLC. A longtime executive and advisor in the biopharmaceutical industry, Mr. Perez served as the Chief Executive Officer of Cubist Pharmaceuticals, Inc. at the time the company was acquired by Merck in 2015. Prior to his tenure as CEO, Mr. Perez held multiple roles at Cubist, including President, Chief Operating Officer and Senior Vice President of Sales and Marketing, where he oversaw the launch of CubicinA .

    Comment?

  17. Ex-Merck scientist pays for insider tradingRead the original story

    Mar 5, 2018 | Chemical and Engineering News

    Former Merck & Co. scientist Yang Xie has agreed to pay the U.S. Securities & Exchange Commission a penalty for insider trading related to Merck's 2015 acquisition of Cubist Pharmaceuticals.

    Comment?

  18. Ex-Merck scientist pays for insider tradingRead the original story

    Mar 5, 2018 | Today's Chemist At Work

    ... Securities & Exchange Commission a penalty for insider trading related to Merck's 2015 acquisition of Cubist Pharmaceuticals. Xie, at the time Merck's director of global health outcomes research, bought shares in Cubist soon after learning that ...

    Comment?

  19. Bacteremia Market to Expand with Significant CAGR During 2017 - 2025Read the original story w/Photo

    Mar 7, 2018 | SBWire

    ... a lipopeptide antibiotic is an FDA approved treatment for MRSA bacteria. The drug is manufactured by Cubist Pharmaceuticals, Inc. under brand name CUBICIN. As majority of the treatment involves prescription of generic drugs, the market is mainly ...

    Comment?

  20. Tetraphase Appoints COORead the original story w/Photo

    Mar 2, 2018 | Contract Pharma Breaking News

    ... joining Tetraphase, Mr. Edwards served as senior director of marketing, Gram Negative Franchise, with Cubist Pharmaceuticals, Inc. (later acquired by Merck), where he was responsible for all pre-launch or post-launch marketing activities for ...

    Comment?